Earnings summaries and quarterly performance for STAAR SURGICAL.
Executive leadership at STAAR SURGICAL.
Board of directors at STAAR SURGICAL.
Research analysts who have asked questions during STAAR SURGICAL earnings calls.
AP
Anthony Petrone
Mizuho Group
5 questions for STAA
Also covers: ADMA, ALC, BSX +22 more
Thomas Stephan
Stifel
5 questions for STAA
Also covers: ALC, GKOS, RXST +1 more
Patrick Wood
Morgan Stanley
4 questions for STAA
Also covers: ALC, BDX, BLCO +17 more
Ryan Zimmerman
BTIG
4 questions for STAA
Also covers: ALC, GEHC, GKOS +23 more
DS
David Saxon
Needham & Company
2 questions for STAA
Also covers: ALC, ALGN, ATEC +11 more
GK
Gursimran Kaur
Wells Fargo & Company
2 questions for STAA
Also covers: MMSI
JY
John Young
Canaccord Genuity - Global Capital Markets
2 questions for STAA
Also covers: ANGO, CVRX, IRTC +2 more
GS
George Sellers
Stephens Inc.
1 question for STAA
Also covers: FNA
James Sidoti
Sidoti & Company
1 question for STAA
Also covers: ANIK, ASRT, GAIA +10 more
MK
Macauley Kilbane
William Blair & Company
1 question for STAA
Also covers: CBLL, CVRX, GKOS +4 more
MK
Margaret Kaczor Andrew
William Blair
1 question for STAA
Also covers: CUTR, DXCM, NARI +2 more
MC
Mason Carrico
Stephens Inc.
1 question for STAA
Also covers: AKYA, CDNA, CSTL +13 more
MO
Matthew O'Brien
Piper Sandler & Co.
1 question for STAA
Also covers: APYX, ATEC, ATRC +18 more
SL
Steven Lichtman
Oppenheimer & Co. Inc.
1 question for STAA
Also covers: ALC, ANGO, COO +12 more
Recent press releases and 8-K filings for STAA.
STAAR Surgical: Defender Capital Reiterates Vote Against Alcon Acquisition
STAA
M&A
Takeover Bid
Proxy Vote Outcomes
- Defender Capital, a 1.5% shareholder of STAAR Surgical (STAA), has reiterated its intention to vote AGAINST the proposed sale of STAAR to Alcon Inc. (ALC).
- The firm believes the acquisition is at the wrong time and price, arguing it does not reflect STAAR's long-term potential or adequate value for shareholders, especially given recent business stabilization and major shareholder support for an independent STAAR.
- Defender Capital also criticized the deal's process as flawed, noting that Glass Lewis recommended against it and ISS called it "deeply flawed," with no new bids emerging after the process was reopened.
- The shareholder vote on the transaction is scheduled for December 19.
6 days ago
STAAR Surgical's Amended Alcon Merger Agreement Receives Analyst and ISS Support
STAA
M&A
Proxy Vote Outcomes
Takeover Bid
- STAAR Surgical's amended merger agreement with Alcon provides stockholders with $30.75 per share in cash, representing a 74% premium to STAAR's 90-day Volume Weighted Average Price as of August 4, 2025.
- Independent industry analysts, including BTIG, Canaccord Genuity, Mizuho, and Needham, have recognized the value of the amended Alcon merger agreement, with Mizuho noting the ~4.5x proposed exit multiple as sufficiently fair.
- Independent proxy advisory firm Institutional Shareholder Services (ISS) has updated its report to recommend that STAAR stockholders vote "FOR" the Alcon transaction.
- The STAAR Board of Directors also recommends that stockholders vote "FOR" the Alcon merger at the virtual Special Meeting scheduled for December 19, 2025, with the record date for voting being October 24, 2025.
7 days ago
STAAR Surgical's Go-Shop Period Expires Amidst Shareholder Opposition to Alcon Merger
STAA
M&A
Proxy Vote Outcomes
Takeover Bid
- STAAR Surgical Company's go-shop period, related to its amended merger agreement with Alcon Inc., expired on December 6, 2025, with no alternative proposals received.
- Alcon Inc. announced an amended merger agreement to acquire STAAR Surgical.
- Yunqi Capital noted Alcon's revised offer to acquire STAAR Surgical for $30.75 per share.
- Broadwood Partners and proxy advisory firm Egan-Jones have reaffirmed their recommendation for shareholders to vote "AGAINST" the proposed acquisition by Alcon. STAAR Surgical has issued a statement to correct misinformation from Broadwood Partners regarding its go-shop process.
Dec 11, 2025, 2:47 PM
STAAR Surgical Sets Record Straight on Go-Shop Process for Alcon Merger
STAA
M&A
Takeover Bid
Proxy Vote Outcomes
- STAAR Surgical issued a statement to correct misinformation from activist investors Broadwood Partners and Yunqi Capital regarding its go-shop process for the pending merger with Alcon.
- The company clarified that FountainVest, identified by activists as a "credible buyer," initiated contact on day 21 of the 30-day go-shop period and subsequently declined to execute a non-disclosure agreement, even after STAAR accepted FountainVest's deletion of a standstill provision.
- The 30-day go-shop period expired on December 6, 2025, with no acquisition proposals received.
- STAAR's CEO, Stephen Farrell, indicated that the company has faced challenges with procedure volumes in China and that now is the right time to sell.
- STAAR encourages stockholders to accept Alcon's increased all-cash offer of $30.75 per share, representing a 74% premium to the 90-day VWAP, with a Special Meeting of Stockholders scheduled for December 19, 2025, to vote on the merger.
Dec 11, 2025, 2:47 PM
STAAR Surgical: Broadwood Partners Opposes Alcon's Amended Acquisition Offer
STAA
M&A
Takeover Bid
- Alcon Inc. announced an amended merger agreement with STAAR Surgical Company.
- Broadwood Partners, holding 30.2% of STAAR's outstanding common stock, continues to oppose the proposed sale of the Company to Alcon, despite Alcon's increased proposed acquisition price.
Dec 9, 2025, 5:39 PM
STAAR Surgical and Alcon Amend Merger Agreement
STAA
M&A
Takeover Bid
Proxy Vote Outcomes
- Alcon has entered into an amended merger agreement to acquire STAAR Surgical for $30.75 per share in cash.
- This revised offer increases the equity value for stockholders by approximately $150 million, bringing the total equity value of the transaction to approximately $1.6 billion.
- The acquisition price represents a 74% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 66% premium to the closing price on August 4, 2025.
- The transaction is anticipated to close in early 2026, subject to customary closing conditions, and is expected to be accretive to Alcon's earnings in year two.
Dec 9, 2025, 1:30 PM
STAAR Surgical Announces Expiration of Go-Shop Period
STAA
M&A
Takeover Bid
Proxy Vote Outcomes
- STAAR Surgical Company announced the expiration of its go-shop period on December 6, 2025, at 11:59 p.m. Eastern Time, related to its amended merger agreement with Alcon Inc..
- No competing acquisition proposals were received during the go-shop period.
- STAAR, with the assistance of its financial advisor, Citi, actively solicited proposals from 21 third parties, with two signing non-disclosure agreements and engaging in discussions, but none submitted a competing offer.
- The company stated that the results of the go-shop process validate the effectiveness of the STAAR Board's process and confirm that Alcon is the right buyer.
Dec 8, 2025, 1:13 PM
STAAR Surgical Reports Q3 2025 Results and Pending Acquisition
STAA
Earnings
M&A
Share Buyback
- STAAR Surgical reported net sales of $94.7 million for the third quarter of 2025, representing a 6.9% year-over-year increase, significantly influenced by $25.9 million recognized from the December 2024 China shipment.
- The company's gross margin improved to 82.2% in Q3 2025, compared to 77.3% in the prior year quarter, primarily due to the timing of cost of sales recognition for the December China Shipment.
- Net income for Q3 2025 was $8.9 million, or $0.18 per diluted share, a decrease from $10.0 million or $0.20 per share in the prior year quarter. However, Adjusted EBITDA increased to $34.6 million, or $0.68 per share, up from $16.2 million or $0.33 per share year-over-year.
- STAAR Surgical announced a pending acquisition by Alcon Inc., and consequently, will not host a conference call to discuss its third quarter 2025 results.
- During Q3 2025, the company repurchased approximately 115,000 shares of its common stock for a total cost of $2.0 million under its $30 million share repurchase program.
Nov 5, 2025, 9:02 PM
STAAR Surgical Postpones Special Meeting of Stockholders Amid Alcon Discussions
STAA
M&A
Proxy Vote Outcomes
- STAAR Surgical Company has postponed its Special Meeting of Stockholders to December 3, 2025, at 8:30 a.m. Pacific Time.
- This postponement is due to ongoing discussions with Alcon regarding a merger agreement.
- The new record date for the Special Meeting is the close of business on October 24, 2025, for stockholders to be eligible to vote.
Oct 27, 2025, 2:52 PM
STAAR Surgical Announces Preliminary Q3 2025 Net Sales Results
STAA
Earnings
M&A
Demand Weakening
- STAAR Surgical reported preliminary net sales of $94.7 million for Q3 2025, an increase of 6.9% compared to $88.6 million in the prior year period.
- This growth was primarily driven by the recognition of $25.9 million from a December 2024 ICL shipment to China, which was paid in full during Q3 2025, and 7.7% growth in net sales outside China.
- The increase was partially offset by lower new orders from Chinese distributors, who reduced their inventory by approximately $80 million to $85 million for the nine months ended September 26, 2025.
- A Special Meeting of Stockholders is scheduled for October 23, 2025, to vote on the Alcon merger proposal.
Oct 20, 2025, 11:45 AM
Quarterly earnings call transcripts for STAAR SURGICAL.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more